FRONTEO Inc. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereafter FRONTEO) is pleased to announce the article search AI system "Amanogawa (trademark)" that supports the efficiency of drug discovery processes and drug discovery innovation in pharmaceutical companies. Patent pending) ”will be announced.

In drug discovery research, in order to keep track of domestic and international drug research trends in a timely manner, it is essential to refer to treatises and medical data on a daily basis and keep updating information related to diseases and compounds. ..In addition, it is said that the probability of reaching a clinical trial from basic research is 3,000 in 5,000 to 1 / 5, and the research period takes 8 to XNUMX years, which is a huge amount of researchers spending to obtain one result. Time and effort are major challenges in drug discovery research.

PubMed is included in the paper search AI system "Amanogawa" to be announced this time.^{※ 1}And Open Targets^{※ 2}The latest database of FRONTEO's original natural language analysis AI engine "Concept Encoder (registered trademark: concept encoder)"^®, Reading: Concept Encoder) ”converts all treatise information into location information.When a researcher enters his or her hypothesis or keyword into "Amanogawa", the hypothesis and the latest papers related to the hypothesis are plotted on a map as location information, and the papers to be referred to can be visually extracted.Furthermore, since "Concept Encoder" analyzes the similarity of the contents of the articles and determines the position on the MAP, the contents of the articles can be specified by the displayed area, or the narrow search can be performed by dragging and dropping on the MAP. It is possible to do it.

"Amanogawa" paper search screen.Each point shows a treatise.It is also possible to select only a part of the plotted papers by dragging and dropping and explore further.
(System introduction:https://lifescience.fronteo.com/pharmaceuticals/Amanogawa/）

"Amanogawa" has the function of visually and intuitively performing the entire treatise search process by analyzing and visualizing the number of treatise information that cannot be read by humans in just one day. It will revolutionize the process of drug discovery research, including narrowing down, analyzing, and even extracting target molecules.In addition, since it is possible to list relevant papers without human bias, it is possible to contribute to the creation of innovative new drugs by constructing new data-driven hypotheses that do not depend on experience or subjectivity. I will.

FRONTEO hopes to contribute to the realization of a disease-free future that cannot be cured by the power of AI by solving problems in drug discovery research.

* 1 PubMed: A database that allows you to search for biological and medical treatises. Created by NCBI (National Center for Biotechnology Information) in NLM (National Library of Medicine).
* 2 Open Targets: Database for discovering drug discovery targets through public-private partnerships

concept encoderabout URL: https://lifescience.fronteo.com/concept-encoder/

"Concept Encoder (registered trademark: conceptencoder®, reading: concept encoder)" is a natural language analysis AI (artificial intelligence) developed by FRONTEO specially in the life science field.It was developed in 2018 with the aim of effectively analyzing and utilizing medical data containing a large amount of free-form text data based on evidence. "Concept Encoder" can be co-analyzed with data other than text, and we are conducting research on co-analysis with numerical data such as gene expression information, vitals and various test values ​​accumulated in the life science field.Patent registration number: Patent No. 6346367

FRONTEOabout URL: https://www.fronteo.com/

FRONTEO uses the in-house developed AI engines "KIBIT (R)" and "Concept Encoder (R)" that specialize in natural language processing to extract meaningful and important information from a huge amount of text data. A data analysis company that supports a company's business. Since its establishment in August 2003, it has been expanding globally to Japan, the United States, South Korea, and Taiwan, focusing on legal tech businesses such as "e-discovery (electronic discovery)" and "digital forensic investigation" that support international litigation of companies. Has been deployed.Based on the AI ​​technology cultivated in the legal tech business, we will expand the business field to the life science field and business intelligence field from 8, and use AI to "turn text data into knowledge" to support drug discovery. , Dementia diagnosis support, financial, personnel, sales support, etc., contributing to solving various corporate issues. Listed on TSE Mothers on June 2014, 2007.The capital is 6 thousand yen (as of March 26, 2,568,651).